|
DengYue Medicine
|
|
|
On September 12, 2024, China’s NMPA officially approved Xeligekimab Injection (Jinlixi), developed by Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., for the treatment of adult patients with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy.
Xeligekimab is a fully human anti-IL-17A monoclonal antibody that inhibits IL-17A signaling and inflammation, offering a novel mechanism for managing chronic inflammatory skin disease.
This milestone adds a new biologic option for Chinese psoriasis patients, and further reflects the growing innovation capacity of China’s biopharmaceutical sector.
—
DengYue Medicine is a Hong Kong-based pharmaceutical wholesaler specializing in the export of Chinese innovative medicines, oncology and hematology treatments, and orphan drugs. |
|
|